Modality
Vaccine
MOA
AuroraAi
Target
BCMA
Pathway
Tau
NarcolepsyCLL
Development Pipeline
Preclinical
~Feb 2022
→ ~May 2023
Phase 1
~Aug 2023
→ ~Nov 2024
Phase 2
Feb 2025
→ Jul 2031
Phase 2Current
NCT06562395
894 pts·CLL
2025-02→2031-07·Recruiting
894 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-07-255.3y awayPh3 Readout· CLL
Trial Timeline
2025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P2/3
Recruit…
Catalysts
Ph3 Readout
2031-07-25 · 5.3y away
CLL
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06562395 | Phase 2/3 | CLL | Recruiting | 894 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| REG-2328 | Regeneron | Phase 1 | BCMA | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 |